Rising formulary restrictions and patient out-of-pocket costs exacerbate prescription abandonment, despite large pharma investments in copay assistance that remain under-recognized by patients. Heightened prior authorizations and utilization management impede access, contributing to a paradox of increasing promotional spending failing to yield prescription conversions. This systemic dysfunction disproportionately impacts vulnerable patients and calls for urgent industry and policy adjustments to improve affordability and access continuity.